These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 11547779

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses.
    Wang D, Bayliss S, Meads C.
    Health Technol Assess; 2011 Jan; 15(5):iii-iv, 1-124. PubMed ID: 21281564
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Utilization management opportunities for palivizumab for prophylaxis of respiratory syncytial virus complications in infants.
    Curtiss FR, Fairman KA.
    J Manag Care Pharm; 2010 Jan; 16(1):59-66. PubMed ID: 20044846
    [No Abstract] [Full Text] [Related]

  • 9. [Palivizumab and bronchiolitis: need to apply the efficiency in order to join clinical practice to scientific studies].
    González de Dios J, Ochoa Sangrador C.
    Med Clin (Barc); 2005 Apr 02; 124(12):478-9. PubMed ID: 15826590
    [No Abstract] [Full Text] [Related]

  • 10. From chimpanzee coryza to palivizumab: changing times for respiratory syncytial virus.
    Ogra PL.
    Pediatr Infect Dis J; 2000 Aug 02; 19(8):774-9; discussion 811-3. PubMed ID: 10959757
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Admission to the intensive care unit for respiratory syncytial virus bronchiolitis: a national survey before palivizumab use.
    Prais D, Schonfeld T, Amir J, Israeli Respiratory Syncytial Virus Monitoring Group.
    Pediatrics; 2003 Sep 02; 112(3 Pt 1):548-52. PubMed ID: 12949282
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness of palivizumab against respiratory syncytial viral infection in high-risk children in Austria.
    Resch B, Gusenleitner W, Nuijten MJ, Lebmeier M, Wittenberg W.
    Clin Ther; 2008 Apr 02; 30(4):749-60. PubMed ID: 18498923
    [Abstract] [Full Text] [Related]

  • 16. Guidelines for the use of palivizumab in infants and young children with congenital heart disease.
    Nakazawa M, Saji T, Ichida F, Oyama K, Harada K, Kusuda S.
    Pediatr Int; 2006 Apr 02; 48(2):190-3. PubMed ID: 16635185
    [No Abstract] [Full Text] [Related]

  • 17. Observational study of respiratory syncytial virus-associated hospitalizations and use of palivizumab in premature infants aged 29-32 weeks.
    Resch B, Gusenleitner W, Müller WD, Haas J.
    Eur J Clin Microbiol Infect Dis; 2006 Feb 02; 25(2):120-2. PubMed ID: 16491302
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.